| # | Title | Journal | Year | Citations |
|---|
|
| 1 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | New England Journal of Medicine | 2015 | 6,992 |
| 2 | Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | New England Journal of Medicine | 2012 | 6,910 |
| 3 | Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer | New England Journal of Medicine | 2006 | 5,497 |
| 4 | Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer | New England Journal of Medicine | 2004 | 4,751 |
| 5 | Nonrigid registration using free-form deformations: application to breast MR images | IEEE Transactions on Medical Imaging | 1999 | 4,382 |
| 6 | Abiraterone and Increased Survival in Metastatic Prostate Cancer | New England Journal of Medicine | 2011 | 3,811 |
| 7 | Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update | Journal of Clinical Oncology | 2013 | 3,396 |
| 8 | Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers | New England Journal of Medicine | 2009 | 3,371 |
| 9 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,158 |
| 10 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Lancet, The | 2000 | 3,057 |
| 11 | Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer | New England Journal of Medicine | 2013 | 2,811 |
| 12 | Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study | Lancet, The | 2017 | 2,413 |
| 13 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial | Lancet Oncology, The | 2015 | 2,409 |
| 14 | Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial | Lancet, The | 2006 | 2,389 |
| 15 | International uniform response criteria for multiple myeloma | Leukemia | 2006 | 2,369 |
| 16 | Fibroblast growth factor signalling: from development to cancer | Nature Reviews Cancer | 2010 | 2,243 |
| 17 | Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer | New England Journal of Medicine | 2008 | 2,107 |
| 18 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Lancet Oncology, The | 2014 | 2,007 |
| 19 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Lancet, The | 2014 | 1,881 |
| 20 | Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma | New England Journal of Medicine | 2014 | 1,875 |
| 21 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2017 | 1,812 |
| 22 | Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology | American Journal of Roentgenology | 2007 | 1,758 |
| 23 | Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations | Neoplasia | 2009 | 1,735 |
| 24 | Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status | Journal of Clinical Oncology | 2011 | 1,734 |
| 25 | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 1,683 |
| 26 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial | Lancet, The | 2011 | 1,678 |
| 27 | Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study | Journal of Clinical Oncology | 2010 | 1,660 |
| 28 | Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial | Lancet, The | 2004 | 1,576 |
| 29 | Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group | Journal of the National Cancer Institute | 2011 | 1,553 |
| 30 | Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study | Lancet Oncology, The | 2020 | 1,545 |
| 31 | Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations | New England Journal of Medicine | 2015 | 1,543 |
| 32 | Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial | Lancet, The | 2017 | 1,542 |
| 33 | Olaparib for Metastatic Castration-Resistant Prostate Cancer | New England Journal of Medicine | 2020 | 1,475 |
| 34 | Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial | Lancet Oncology, The | 2011 | 1,452 |
| 35 | Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial | Lancet Oncology, The | 2016 | 1,405 |
| 36 | Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 1,402 |
| 37 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia | 2022 | 1,398 |
| 38 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials | Lancet Oncology, The | 2015 | 1,392 |
| 39 | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial | Lancet, The | 2007 | 1,368 |
| 40 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial | Lancet, The | 2014 | 1,344 |
| 41 | Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer | New England Journal of Medicine | 2015 | 1,286 |
| 42 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer | New England Journal of Medicine | 2016 | 1,269 |
| 43 | Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer | New England Journal of Medicine | 2021 | 1,261 |
| 44 | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 1,256 |
| 45 | Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2017 | 1,237 |
| 46 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial | Lancet, The | 2015 | 1,212 |
| 47 | Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer | Lancet, The | 1998 | 1,199 |
| 48 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse | British Journal of Cancer | 2000 | 1,157 |
| 49 | 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years | New England Journal of Medicine | 2017 | 1,152 |
| 50 | SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth | Cell Metabolism | 2008 | 1,142 |
